fluoxetine has been researched along with Anti-MuSK Myasthenia Gravis in 2 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the weight reducing effect of fluoxetine on steroid-induced obesity, we conducted an open, clinical intervention study of 20-40 mg/day fluoxetine, 24 weeks duration." | 9.09 | Fluoxetine treatment for weight reduction in steroid-induced obesity: a pilot study in myasthenia gravis patients. ( Achiron, A; Barak, Y; Noy, S; Pinhas-Hamiel, O, 1999) |
| "To evaluate the weight reducing effect of fluoxetine on steroid-induced obesity, we conducted an open, clinical intervention study of 20-40 mg/day fluoxetine, 24 weeks duration." | 5.09 | Fluoxetine treatment for weight reduction in steroid-induced obesity: a pilot study in myasthenia gravis patients. ( Achiron, A; Barak, Y; Noy, S; Pinhas-Hamiel, O, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cetin, H | 1 |
| Webster, R | 1 |
| Liu, WW | 1 |
| Nagaishi, A | 1 |
| Koneczny, I | 1 |
| Zimprich, F | 1 |
| Maxwell, S | 1 |
| Cossins, J | 1 |
| Beeson, D | 1 |
| Vincent, A | 1 |
| Achiron, A | 1 |
| Barak, Y | 1 |
| Noy, S | 1 |
| Pinhas-Hamiel, O | 1 |
1 trial available for fluoxetine and Anti-MuSK Myasthenia Gravis
| Article | Year |
|---|---|
Fluoxetine treatment for weight reduction in steroid-induced obesity: a pilot study in myasthenia gravis patients.
Topics: Adult; Anti-Inflammatory Agents; Antidepressive Agents, Second-Generation; Body Mass Index; Female; | 1999 |
1 other study available for fluoxetine and Anti-MuSK Myasthenia Gravis
| Article | Year |
|---|---|
Myasthenia gravis AChR antibodies inhibit function of rapsyn-clustered AChRs.
Topics: Adolescent; Adult; Aged; Autoantibodies; Bungarotoxins; Cell Line; Electrophysiological Phenomena; F | 2020 |